Farxiga FAERS Safety Signals: What Post-Market Data Show About Dapagliflozin Safety

How FAERS Works and Why It Matters for Dapagliflozin

The FDA Adverse Event Reporting System is the primary post-market safety surveillance tool the FDA uses to detect drug safety signals after approval. FAERS collects voluntary reports from healthcare professionals, patients, and manufacturers. It does not prove causation. It identifies patterns worth investigating.

Signal Detection vs. Causation

For dapagliflozin, FAERS has been particularly active. The drug received initial FDA approval on January 8, 2014, for glycemic control in type 2 diabetes [2]. Within the first two years of market availability, several adverse event clusters emerged that prompted formal FDA safety communications. Each signal triggered a review cycle: FAERS data flagged the pattern, FDA epidemiologists evaluated the signal using the Empirical Bayes Geometric Mean (EBGM) scoring method, and the agency then issued safety communications or label changes when warranted [3].

Limitations of Voluntary Reporting

FAERS reports are subject to well-documented biases. The FDA estimates that FAERS captures only 1% to 10% of actual adverse events for any given drug [3]. Reporting rates spike after media coverage or FDA safety communications, creating temporal artifacts. Reports lack denominators (total patients exposed), making incidence calculations impossible from FAERS data alone. For dapagliflozin, this means the raw case counts overrepresent dramatic or novel events like Fournier gangrene and underrepresent common but less alarming reactions like polyuria.

Diabetic Ketoacidosis: The First Major Signal

DKA in patients taking SGLT2 inhibitors was the first class-wide safety signal to reach public attention. Between March 2013 and May 2015, the FDA identified 73 cases of ketoacidosis in patients taking SGLT2 inhibitors, including dapagliflozin [4]. Many cases were atypical. Blood glucose levels were only mildly elevated or even normal, a presentation now called euglycemic DKA (euDKA).

Euglycemic DKA Presentation

The mechanism is pharmacologically predictable. SGLT2 inhibitors lower plasma glucose by promoting renal glucose excretion. This reduces insulin secretion while glucagon rises, shifting metabolism toward fatty acid oxidation and ketogenesis. The result: ketoacidosis without the expected hyperglycemia above 250 mg/dL.

Label Changes and Clinical Impact

The FDA issued a Drug Safety Communication on December 4, 2015, warning about the DKA risk [4]. The dapagliflozin label was updated in 2016 to include DKA warnings and instructions to discontinue the drug if ketoacidosis is suspected. The European Medicines Agency (EMA) followed with a similar review, concluding that the risk was rare but serious, estimated at roughly 0.1 to 1 per 1,000 patient-years for the SGLT2 class [5].

Dr. Robert Eckel, past president of the American Heart Association, noted in a 2016 review: "Clinicians must maintain a high index of suspicion for DKA in any SGLT2 inhibitor-treated patient presenting with nausea, vomiting, or malaise, even when glucose values appear reassuring" [6].

Triggers include surgery, prolonged fasting, acute illness, and insulin dose reductions. Current prescribing guidance recommends holding dapagliflozin at least 3 days before scheduled surgery, though some guidelines extend this to 4 days [5].

Fournier Gangrene: A Rare but Severe Complication

In August 2018, the FDA issued a safety warning about necrotizing fasciitis of the perineum (Fournier gangrene) across all SGLT2 inhibitors, including dapagliflozin [7]. The agency identified 55 unique cases of Fournier gangrene associated with SGLT2 inhibitors from March 2013 to January 2019. Over the preceding 30 years before SGLT2 inhibitor availability, only 19 cases had been reported across all other antidiabetic medications combined [7].

Case Demographics

The median age was 56 years, and cases affected both men and women. All 55 patients required hospitalization. Some required multiple surgeries. Several died.

Mechanism and Risk Factors

The proposed mechanism centers on glycosuria. SGLT2 inhibitors increase urinary glucose concentration, creating a favorable environment for bacterial overgrowth in the perineal region. Patients with obesity, prior perineal surgery, or recurrent genital infections may carry elevated risk, though the condition has also been reported in patients without clear predisposing factors [7].

The absolute risk remains very low. A 2020 pharmacovigilance analysis using FAERS data calculated a reporting odds ratio (ROR) of 9.2 (95% CI: 5.5 to 15.3) for Fournier gangrene with SGLT2 inhibitors compared to other diabetes drugs [8]. The label now instructs patients to seek immediate medical attention for tenderness, redness, or swelling in the genital or perineal area, accompanied by fever or malaise.

Urinary Tract and Genital Infections

Increased urogenital infections were identified during the pre-approval clinical trial program and reinforced by post-market FAERS data. The dapagliflozin prescribing information reports genital mycotic infections in approximately 6.9% of women and 2.7% of men in pooled clinical trial data, compared to 1.5% and 0.3% with placebo [2].

Serious UTI Reports

The more concerning FAERS signal involved serious urinary tract infections requiring hospitalization, including urosepsis and pyelonephritis. In a December 2015 label revision, the FDA strengthened the UTI warning language based on FAERS case review. A post-market analysis of the FDA Sentinel system, which draws on electronic health record and claims data from over 100 million covered lives, provided better-powered estimates than FAERS alone [9].

Risk Mitigation

Current label guidance recommends evaluating patients for signs and symptoms of UTI and treating promptly. Patients with a history of recurrent UTIs may need closer monitoring. Adequate hydration is emphasized to reduce infection risk and mitigate volume depletion.

Acute Kidney Injury: Signal Refined by Trial Data

The FDA issued a safety communication in June 2016 warning about AKI associated with dapagliflozin and canagliflozin [10]. FAERS had accumulated 101 cases of AKI across the two drugs. Many patients had identifiable risk factors: concurrent use of diuretics, ACE inhibitors, or ARBs, plus volume depletion from illness or inadequate fluid intake.

Early Warnings vs. Later Evidence

This signal is notable because subsequent randomized trial data shifted the clinical narrative. DAPA-CKD (N=4,304) demonstrated that dapagliflozin 10 mg reduced the composite endpoint of sustained eGFR decline of 50% or greater, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61, 95% CI: 0.51 to 0.72, P<0.001) compared to placebo in patients with CKD [11].

The "Initial Dip" Phenomenon

The apparent contradiction between FAERS AKI signals and trial-demonstrated renal protection reflects the known hemodynamic effect of SGLT2 inhibitors. Dapagliflozin causes an initial, reversible decline in eGFR of 3 to 5 mL/min/1.73 m² within the first two weeks. This tubuloglomerular feedback-mediated dip reduces intraglomerular pressure and is now understood to be the mechanism that provides long-term nephroprotection [11]. Early FAERS reports may have captured clinical responses to this expected dip, with clinicians interpreting the eGFR decline as drug-induced kidney injury.

The FDA updated the dapagliflozin label in 2021 to include the CKD indication, effectively acknowledging the renal benefit while maintaining monitoring recommendations for AKI risk in volume-depleted patients [2].

Volume Depletion and Hypotension

FAERS data show a consistent signal for volume depletion, dehydration, and hypotension, especially in elderly patients and those receiving loop diuretics. The mechanism is straightforward: dapagliflozin promotes osmotic diuresis through glycosuria, increasing urine output by approximately 375 mL per day [12].

Populations at Highest Risk

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of type 2 diabetes states: "SGLT2 inhibitors should be used with caution in older adults on concurrent diuretic therapy, with consideration given to dose adjustment of the diuretic rather than avoidance of the SGLT2 inhibitor" [13]. Patients with eGFR <30 mL/min/1.73 m² lose much of the glycosuric effect, though cardiorenal benefits persist through non-glycemic mechanisms.

Practical Monitoring Steps

Blood pressure should be checked at baseline and at follow-up visits. Patients on thiazide or loop diuretics may need diuretic dose reductions when starting dapagliflozin. Symptoms to watch: dizziness on standing, lightheadedness, and orthostatic changes.

Lower Limb Amputation: A Signal That Did Not Stick

Canagliflozin carried a boxed warning for lower limb amputations based on CANVAS trial data showing a twofold increase in amputations (6.3 vs. 3.4 per 1,000 patient-years) [14]. FAERS data for dapagliflozin did not replicate this signal. Neither DAPA-HF (N=4,744) nor DECLARE-TIMI 58 (N=17,160) found an increased amputation risk with dapagliflozin [1][15]. The FDA did not apply the amputation warning to dapagliflozin, and in 2020 removed the boxed warning from canagliflozin after broader data accumulation suggested the risk was lower than initially estimated [14].

This episode illustrates an important principle of FAERS interpretation. Signals detected for one drug in a class do not automatically apply to all class members. Molecular differences, selectivity profiles, and pharmacokinetic properties produce meaningfully different safety profiles within the SGLT2 inhibitor class.

Bladder Cancer: An Early Concern Resolved

During dapagliflozin's initial FDA review in 2011, a numerical imbalance in bladder cancer cases (9 in the dapagliflozin group vs. 1 in the placebo/comparator group) led the FDA to issue a complete response letter, delaying approval [2]. The agency requested additional data. A subsequent analysis with longer follow-up did not confirm a causal relationship, and dapagliflozin received approval in January 2014 with a label notation about the imbalance. FAERS monitoring over the following decade has not generated a reinforcing signal, and the EMA's 2021 periodic safety update report concluded the evidence did not support a causal association between dapagliflozin and bladder cancer [16].

Balancing FAERS Signals Against Proven Benefits

Post-market safety signals exist in tension with large, well-powered randomized controlled trials demonstrating cardiovascular and renal benefits.

Trial Evidence for Benefit

DAPA-HF enrolled 4,744 patients with heart failure and ejection fraction of 40% or less. Dapagliflozin 10 mg reduced the primary composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI: 0.65 to 0.85, P<0.001) compared to placebo, with a number needed to treat of 21 over a median 18.2 months [1]. DELIVER (N=6,263) extended this benefit to patients with heart failure and ejection fraction above 40% [17].

A Risk-Benefit Framework

Prescribers should approach FAERS data as hypothesis-generating, not definitive. The system excels at detecting rare events that trials are underpowered to capture, like Fournier gangrene. It is less reliable for quantifying risk or establishing causation. Clinical decisions should integrate FAERS signals with trial evidence, patient-level risk factors, and guideline recommendations. For most indicated patients, the cardiovascular mortality reduction and renal protection provided by dapagliflozin outweigh the identified post-market risks when appropriate monitoring is in place.

Monitoring at minimum should include: renal function at baseline and periodically thereafter, blood pressure assessment, symptom screening for genital and urinary infections, and patient education about DKA warning signs (nausea, vomiting, abdominal pain, fatigue, and dyspnea). Hold dapagliflozin 3 to 4 days before elective surgery and during acute illness with reduced oral intake.